Moreover, it is important to analyze the efficacy of multi-kinase/BRAF-inhibitor, sorafenib, in addition to other specific inhibitors of the EGFR as well as PI3K signaling pathway, in the treatment of CRC to further identify novel therapeutic targets. The gene discussed is PIK3CA; the disease is colorectal carcinoma.